Placebo News and Research

RSS

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

What is behind the inconsistent results of COVID-19 clinical trials?

“Most clinical studies of antiviral drugs for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have failed to observe a statistically significant effect, which may be due to poor designs of clinical trials.”

12 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Common orthopedic procedures lack high quality evidence, analysis reveals

Most common bone and joint procedures, such hip replacements and shoulder repair surgery, are not backed up by high quality evidence, mainly because of a lack of definitive trials, suggests an analysis of data published by The BMJ today.

8 Jul 2021

New analysis finds muscle relaxant drugs to be largely ineffective for low back pain

Muscle relaxant drugs are largely ineffective for low back pain, despite being widely prescribed for this condition, suggests an analysis of the latest evidence published by The BMJ today.

8 Jul 2021

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.

7 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Individual variation in viral dynamics could underlie inconsistencies in COVID-19 antiviral treatments

Due to variation in viral dynamics between people, improving the experimental design could help develop effective antiviral treatments for COVID-19.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Repurposing existing medications to reduce the severity of sleep apnea

In an Australian world-first, researchers have successfully repurposed two existing medications to reduce the severity of sleep apnea in people by at least 30 per cent.

2 Jul 2021

High omega 3 diet associated with reduction of headaches

Eating a diet rich in omega 3 (n-3) fatty acids reduces the frequency of headaches compared with a diet with normal intake of omega 3 and omega 6 (n-6) fatty acids, finds a study published by The BMJ today.

2 Jul 2021

Prenatal THC and CBD exposure impairs offspring's ability to respond to fluoxetine

Scientists at Indiana University have found that significant amounts of the two main components of cannabis, THC and CBD, enter the embryonic brain of mice in utero and impair the mice's ability as adults to respond to fluoxetine, a drug commonly used to treat anxiety and depression and known by the brand name Prozac.

1 Jul 2021

Strength training for breathing muscles lowers blood pressure, improves vascular health

Working out just five minutes daily via a practice described as "strength training for your breathing muscles" lowers blood pressure and improves some measures of vascular health as well as, or even more than, aerobic exercise or medication, new CU Boulder research shows.

30 Jun 2021

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.

30 Jun 2021

Tackling emerging SARS-CoV-2 variants

An international team of authors has published a special report in The New England Journal of Medicine titled 'SARS-CoV-2 Variants and Vaccines’, which presents global strategies for the possible escape from vaccine-elicited immunity.

29 Jun 2021

Metabolic activators can reduce recovery time in patients with mild-to-moderate Covid-19

Metabolic activators were found to reduce recovery time by as many as 3.5 days in patients with mild-to-moderate Covid-19, according to a Swedish-British study published today in Advanced Science.

28 Jun 2021

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

Oncotarget published "Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib" which reported that this study investigated the association of the IGF/CTP score with overall survival and progression-free survival of HCC patients treated with sorafenib.

28 Jun 2021

Placebo News and Research

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

What is behind the inconsistent results of COVID-19 clinical trials?

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Common orthopedic procedures lack high quality evidence, analysis reveals

New analysis finds muscle relaxant drugs to be largely ineffective for low back pain

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Antibiotic clofoctol shows potential against SARS-CoV-2

Individual variation in viral dynamics could underlie inconsistencies in COVID-19 antiviral treatments

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Repurposing existing medications to reduce the severity of sleep apnea

High omega 3 diet associated with reduction of headaches

Prenatal THC and CBD exposure impairs offspring's ability to respond to fluoxetine

Strength training for breathing muscles lowers blood pressure, improves vascular health

Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

Tackling emerging SARS-CoV-2 variants

Metabolic activators can reduce recovery time in patients with mild-to-moderate Covid-19

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

An oral pill for COVID-19? Molnupiravir shows promise

Many people with fibromyalgia substitute CBD for opioids and pain medications, finds study

A study on hospitalized COVID-19 patients who received plasma therapy

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News